MedTrace Logo

Open Label Immunotherapy Trial for Ovarian Cancer

NCT03556566 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-08-30

No results posted yet for this study

Summary

This Phase II will evaluate a new type of ovarian cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. We will test new tableted preparation, V3-OVA, obtained from hydrolyzed, inactivated blood and tumors of patients with cancer of ovaries. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.

Conditions

Interventions

BIOLOGICAL

Tableted vaccine (V3-OVA) containing ovarian cancer antigens

One pill of V3-OVA per day for three months

Sponsors & Collaborators

  • Immunitor LLC

    lead INDUSTRY

Principal Investigators

  • Aldar Bourinbaiar, PhD, MD/PhD · Immunitor LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-11-30
Completion
2019-12-31

Countries

  • Mongolia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03556566 on ClinicalTrials.gov